<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39368119</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">0975-4466</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Annals of Saudi medicine</Title><ISOAbbreviation>Ann Saudi Med</ISOAbbreviation></Journal><ArticleTitle>Impact of SARS-CoV-2 infection and vaccination on cesarean section outcomes: a retrospective analysis.</ArticleTitle><Pagination><StartPage>306</StartPage><EndPage>318</EndPage><MedlinePgn>306-318</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5144/0256-4947.2024.306</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Pregnant individuals have faced unique challenges during the COVID-19 pandemic, necessitating a closer examination of maternal and fetal health outcomes.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Investigate the morbidity and mortality associated with SARS-CoV-2 infection among pregnant individuals, considering vaccination status and variant strains.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Retrospective cohort.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">Tertiary state hospital.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">Patients who underwent cesarean sections were categorized into three periods: pre-vaccination (before 31 August 2021), early post-vaccination (from September 2021), and late post-vaccination (aligned with 70% immunization coverage by 2 September 2021). Data collected included demographic information (age, gravidity, parity count, gestational age, newborn APGAR scores), cesarean section indications, chronic diseases, vaccination status, vaccine type and doses, SARS-CoV-2 variant status, ICU admission, and mortality due to COVID-19.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">ICU admission and mortality rates, focusing on the impact of SARS-CoV-2 infection and vaccination status.</AbstractText><AbstractText Label="SAMPLE SIZE" NlmCategory="UNASSIGNED">297 COVID PCR-positive symptomatic patients who underwent cesarean sections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the pre-vaccination group, there were 13 mortalities (8.1%) compared to 9 (6.6%) post-vaccination (<i>P</i>=.610). Maternal ARDS was seen in 46.2% of pre-vaccination mortalities versus 11.1% post-vaccination (<i>P</i>=.045). COVID-19 delta variant patients had higher ICU admission (80%) and mortality rates (40%). Rates of COVID-19 PCR-positive cesarean sections, ICU admissions, and mortality declined significantly in early (<i>P</i>=.021, <i>P</i>=.004, <i>P</i>=.009), respectively and late post-vaccination periods (<i>P</i>&lt;.001, <i>P</i>&lt;.001, <i>P</i>=.0019), respectively. Vaccinated patients had no ICU admissions or mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Vaccination against COVID-19 is crucial for pregnant individuals as it significantly reduces the risk of severe illness. While vaccines offer substantial protection, the pandemic's acute phase might be waning, yet COVID-19 remains a global threat, particularly in regions with limited vaccine access. Continued vigilance and proactive measures are essential to mitigate ongoing risks and the emergence of new variant strains.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="UNASSIGNED">Retrospective observational design and the single-center setting, which may affect the generalizability of the findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeniocak</LastName><ForeName>Ali Selcuk</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-8149-6348</Identifier><AffiliationInfo><Affiliation>From the Department of Obstetrics and Gynecology, T.C. Sağlık Bakanlığı Başakşehir Çam ve Sakura Şehir Hastanesi, Basaksehir, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tercan</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics and Gynecology, T.C. Sağlık Bakanlığı Başakşehir Çam ve Sakura Şehir Hastanesi, Basaksehir, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagdeviren</LastName><ForeName>Emrah</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics and Gynecology, T.C. Sağlık Bakanlığı Başakşehir Çam ve Sakura Şehir Hastanesi, Basaksehir, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arabaci</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics and Gynecology, T.C. Sağlık Bakanlığı Başakşehir Çam ve Sakura Şehir Hastanesi, Basaksehir, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arabaci</LastName><ForeName>Emine Elif Genc</ForeName><Initials>EEG</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics and Gynecology, T.C. Sağlık Bakanlığı Başakşehir Çam ve Sakura Şehir Hastanesi, Basaksehir, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>Ann Saudi Med</MedlineTA><NlmUniqueID>8507355</NlmUniqueID><ISSNLinking>0256-4947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>16</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39368119</ArticleId><ArticleId IdType="pmc">PMC11454973</ArticleId><ArticleId IdType="doi">10.5144/0256-4947.2024.306</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorbalenya A, Baker S, Baric RS, de Groot R, Drosten C, Gulyaeva AA, et al. . The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature microbiology. 2020. Mar 2;5(4):536–44. doi:10.1038/s41564-020-0695-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0695-z</ArticleId><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Annals of internal medicine. 2021. Jan;174(1):69–79. doi:10.7326/m20-5008</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-5008</ArticleId><ArticleId IdType="pmc">PMC7505025</ArticleId><ArticleId IdType="pubmed">32941052</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2020) Statement on the second meeting of the International Health Regulations Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).</Citation></Reference><Reference><Citation>World Health Organization (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020 Geneva, Switzerland. 2020:3–5.</Citation></Reference><Reference><Citation>Hayawi K, Shahriar S, Serhani MA, Alashwal H, Masud MM. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines. 2021. Nov 10;9(11):1305. DOI: 10.3390/vaccines9111305</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111305</ArticleId><ArticleId IdType="pmc">PMC8622454</ArticleId><ArticleId IdType="pubmed">34835238</ArticleId></ArticleIdList></Reference><Reference><Citation>La Rosa G, Mancini P, Ferraro GB, Veneri C, Iaconelli M, Lucentini L, et al. . Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. Water research. 2021. Jun 1;197:117104. DOI: 10.1016/j.watres.2021.117104</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2021.117104</ArticleId><ArticleId IdType="pmc">PMC8018700</ArticleId><ArticleId IdType="pubmed">33857895</ArticleId></ArticleIdList></Reference><Reference><Citation>Piret J, Boivin G. Pandemics throughout history. Frontiers in microbiology. 2021. Jan 15;11:631736. DOI: 10.3389/fmicb.2020.631736</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.631736</ArticleId><ArticleId IdType="pmc">PMC7874133</ArticleId><ArticleId IdType="pubmed">33584597</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2020) Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. 9240000917.</Citation></Reference><Reference><Citation>World Health Organization (2020) Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected Interim guidance, 19 March 2020.</Citation></Reference><Reference><Citation>Control CfD Overview of testing for SARS-CoV-2 (COVID-19)., Prevention. (2020)</Citation></Reference><Reference><Citation>McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, et al. . Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. The Lancet. 2022. Jan 8;399(10320):152–60. doi:10.1016/s0140-6736(21)02226-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02226-1</ArticleId><ArticleId IdType="pmc">PMC8565933</ArticleId><ArticleId IdType="pubmed">34741818</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. . Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. New England Journal of Medicine. 2021. Oct 7;385(15):1355–71. doi:10.1056/NEJMoa2110362</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110362</ArticleId><ArticleId IdType="pmc">PMC8451184</ArticleId><ArticleId IdType="pubmed">34496194</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021. May 15;397(10287):1819–29. doi:10.1016/s0140-6736(21)00947-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021. May 1;397(10285):1646–57. doi:10.1016/s0140-6736(21)00677-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00677-2</ArticleId><ArticleId IdType="pmc">PMC8064669</ArticleId><ArticleId IdType="pubmed">33901420</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Het al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine. 2021. Apr 15;384(15):1412–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Péju E, Belicard F, Silva S, Hraiech S, Painvin B, Kamel T, et al. . Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study. Intensive Care Medicine. 2022. Sep;48(9):1185–96.doi:10.1007/s00134-022-06833-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06833-8</ArticleId><ArticleId IdType="pmc">PMC9383668</ArticleId><ArticleId IdType="pubmed">35978137</ArticleId></ArticleIdList></Reference><Reference><Citation>Sağlik Bakanliği T.C. (2021) Covid-19 Aşisi Bilgilendirme Platformu. https://covid19asi.saglik.gov.tr
Accessed 15 July 2021</Citation></Reference><Reference><Citation>Erdal D, Şaşmaz CT. EN AZ İKİ DOZ COVID-19 AŞI KAPSAYICILIK HIZI İLE VAKA İNSİDANSI ARASINDAKİ KORELASYONUN DEĞERLENDİRİLMESİ: EKOLOJİK TİPTE BİR ÇALIŞMA. ESTÜDAM Halk Sağlığı Dergisi. 2023. May 1;8(2):142–50.</Citation></Reference><Reference><Citation>Tsaban G, Ben-Shimol S. (2017) Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine. 35(22):2882–91. Epub 2017/04/30. doi: 10.1016/j.vaccine.2017.04.032. PubMed PMID: 28449971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.04.032</ArticleId><ArticleId IdType="pubmed">28449971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sağlık Bakanlığ TC (2021) COVID-19 Solunum Sistemi Hastalıklarının Yaygın Olduğu Dönemde Sağlık Kuruluşlarında Gebe Takibi, https://covid19.saglik.gov.tr/TR-75284/covid-19-solunum-sistemi-hastaliklarinin-yaygin-oldugu-donemde-saglik-kuruluslarinda-gebe-takibi.html
(Accessed 06 August 2024)</Citation></Reference><Reference><Citation>Villalaín C, Herraiz I, Luczkowiak J, Pérez-Rivilla A, Folgueira MD, Mejía I, et al. . Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. PLoS One. 2020. Nov 30;15(11):e0243029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703887</ArticleId><ArticleId IdType="pubmed">33253283</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2024) WHO coronavirus (COVID-19) dashboard. https://data.who.int/dashboards/covid19. Accessed 02 May 2024</Citation></Reference><Reference><Citation>Sağlik Bakanliği T.C. (2024) Covid-19 Aşisi Bilgilendirme Platformu. https://covid19asi.saglik.gov.tr. Accessed 02 May 2024)</Citation></Reference><Reference><Citation>Firouzabadi N, Ghasemiyeh P, Moradishooli F, Mohammadi-Samani S. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. International immunopharmacology. 2023. Apr 1;117:109968. DOI: 10.1016/j.intimp.2023.109968</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109968</ArticleId><ArticleId IdType="pmc">PMC9977625</ArticleId><ArticleId IdType="pubmed">37012880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortner A, Schumacher D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries. 2021. Jan;9(1). DOI: 10.15190/d.2021.1</Citation><ArticleIdList><ArticleId IdType="doi">10.15190/d.2021.1</ArticleId><ArticleId IdType="pmc">PMC8101362</ArticleId><ArticleId IdType="pubmed">33969180</ArticleId></ArticleIdList></Reference><Reference><Citation>Branswell H. A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines. STAT, Boston, Retrieved. 2021. Jan;14.</Citation></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International journal of infectious diseases. 2022. Jan 1;114:252–60. DOI: 10.1016/j.ijid.2021.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants. Medical science monitor: international medical journal of experimental and clinical research. 2022;28:e936523-1, DOI: 10.12659/MSM.936523</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.936523</ArticleId><ArticleId IdType="pmc">PMC8897963</ArticleId><ArticleId IdType="pubmed">35228506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Mulholland K. Effectiveness of an inactivated SARS-CoV-2 vaccine. New England Journal of Medicine. 2021. Sep 2;385(10):946–8. DOI: 10.1056/NEJMe2111165</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111165</ArticleId><ArticleId IdType="pmc">PMC8427532</ArticleId><ArticleId IdType="pubmed">34469651</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Wang R, Gilby NB, Wei GW. Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. Journal of chemical information and modeling. 2022. Jan 6;62(2):412–22. DOI: 10.1021/acs.jcim.1c01451</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Xiao J, Deng A, Zhang Y, Zhuang Y, Hu T,et al. . Transmission dynamics of an outbreak of the COVID-19 Delta variant B. 1.617. 2–Guangdong Province, China, May–June 2021. China CDC weekly. 2021. Jul 7;3(27):584. DOI: 10.46234/ccdcw2021.148</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.148</ArticleId><ArticleId IdType="pmc">PMC8392962</ArticleId><ArticleId IdType="pubmed">34594941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanches PR, Charlie-Silva I, Braz HL, Bittar C, Calmon MF, Rahal P, et al. . Recent advances in SARS-CoV-2 spike protein and RBD mutations comparison between new variants alpha (B. 1.1. 7, United Kingdom), Beta (B. 1.351, South Africa), Gamma (P. 1, Brazil) and delta (B. 1.617. 2, India). Journal of virus eradication. 2021. Sep 1;7(3):100054. DOI: 10.1016/j.jve.2021.100054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jve.2021.100054</ArticleId><ArticleId IdType="pmc">PMC8443533</ArticleId><ArticleId IdType="pubmed">34548928</ArticleId></ArticleIdList></Reference><Reference><Citation>Radvak P, Kwon HJ, Kosikova M, Ortega-Rodriguez U, Xiang R, Phue JN, et al. . SARS-CoV-2 B. 1.1. 7 (alpha) and B. 1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nature communications. 2021. Nov 12;12(1):6559. DOI: 10.1038/s41467-021-26803-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26803-w</ArticleId><ArticleId IdType="pmc">PMC8589842</ArticleId><ArticleId IdType="pubmed">34772941</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Yon DK, Lee SW, Butler L, Koyanagi A, Jacob L, et al. . Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis. Reviews in Medical Virology. 2023. May;33(3):e2434. doi:10.1002/rmv.2434</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2434</ArticleId><ArticleId IdType="pubmed">36896895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hameed BH, Thamir AR, Jassim H, Ali H. Maternal and perinatal outcome of pregnant women with COVID 19, a tertiary centre experience in Iraq-A Case Series. JPMA The Journal of the Pakistan Medical Association. 2021. Dec 1;71(12):S174–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan M, Appiah-Sakyi K, Oliparambil A, Pullattayil AK, Lindow SW, Ahmed B, et al. . A Meta-Analysis of the Global Stillbirth Rates during the COVID-19 Pandemic. J Clin Med. 12(23). 2023. Nov 21;12(23):7219. Epub 2023/12/09. doi: 10.3390/jcm12237219. PubMed PMID: 38068270; PubMed Central PMCID: PMCPMC10707675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12237219</ArticleId><ArticleId IdType="pmc">PMC10707675</ArticleId><ArticleId IdType="pubmed">38068270</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir BC, Albayrak O, Aslan K. The impact of Coronavirus disease-19 on pregnancy outcomes, a case series. Gynecology Obstetrics &amp; Reproductive Medicine. 2023. Mar 17;29(1):30–5.</Citation></Reference><Reference><Citation>World Health Organization (2024) COVID-19 advice for the public: Getting vaccinated
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice. Accessed 02 May 2024</Citation></Reference><Reference><Citation>US Centers for Disease Control and Prevention. (2024) CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season
https://www.cdc.gov/media/releases/2023/p0912-COVID-19-Vaccine.html. Accessed 02 May 2024</Citation></Reference><Reference><Citation>World Health Organization (2023) Statement on the antigen composition of COVID-19 vaccines
https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines. Accessed 02 May 2024</Citation></Reference><Reference><Citation>US Centers for Disease Control and Prevention (2024) COVID Data Tracker
https://covid.cdc.gov/covid-data-tracker/#pregnancy-data. Accessed 02 May 2024</Citation></Reference><Reference><Citation>Norman M, Magnus MC, Söderling J, Juliusson PB, Navér L, Örtqvist AK, et al. . Neonatal Outcomes After COVID-19 Vaccination in Pregnancy. Jama. 2024. Feb 6;331(5):396–407. Epub 2024/02/06. doi: 10.1001/jama.2023.26945. PubMed PMID: 38319332; PubMed Central PMCID: PMCPMC10848052 Research Council of Norway, NordForsk, and European Research Council during the conduct of the study. No other disclosures were reported.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.26945</ArticleId><ArticleId IdType="pmc">PMC10848052</ArticleId><ArticleId IdType="pubmed">38319332</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnalla M, Stern D, Colchero MA, Rangel-Moreno K, Basto-Abreu A, Alpuche-Aranda CM, et al. . Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over. Vaccine. 2024. May 22;42(14):3273–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">38653678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>